The combined anti-viral effects of both CCR5 CRISPR/Cas9 knockout and C46 HIV-1 fusion inhibitor provided a broad-spectrum effect for both R5- and X4-tropic infections in in vitro testing. The gene discussed is CCR5; the disease is infection.